Elize Pietersen1, Elisa Ignatius2, Elizabeth M Streicher3, Barbara Mastrapa4, Xavier Padanilam5, Anil Pooran1, Motasim Badri6, Maia Lesosky7, Paul van Helden3, Frederick A Sirgel3, Robin Warren3, Keertan Dheda8. 1. Lung Infection and Immunity Unit, Division of Pulmonology and University of Cape Town Lung Institute, Department of Medicine, University of Cape Town, Cape Town, South Africa. 2. Department of Internal Medicine, Emory University School of Medicine, Emory University, Atlanta, GA, USA. 3. Department of Science and Technology and National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, and Medical Research Council Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa. 4. Gordonia Provincial Hospital, Upington, South Africa. 5. Sizwe Tropical Diseases Hospital, Johannesburg, South Africa. 6. Department of Medicine, University of Cape Town, Cape Town, South Africa; College of Sciences and Health Professions, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia. 7. Department of Medicine, University of Cape Town, Cape Town, South Africa. 8. Lung Infection and Immunity Unit, Division of Pulmonology and University of Cape Town Lung Institute, Department of Medicine, University of Cape Town, Cape Town, South Africa. Electronic address: keertan.dheda@uct.ac.za.
Abstract
BACKGROUND: Long-term treatment-related outcomes in patients with extensively drug-resistant (XDR) tuberculosis are unknown. We followed up a cohort of patients to address knowledge gaps. METHODS: Between March, 2008, and August, 2012, we prospectively followed up a cohort of 107 patients from three provinces in South Africa, who had been diagnosed with XDR tuberculosis between August 2002, and February, 2008. Available isolates from 56 patients were genotyped to establish strain type and used for extended susceptibility testing. FINDINGS: All patients were treated empirically as inpatients with a median of eight drugs (IQR six to ten). 44 patients (41%) had HIV. 36 (64%) of 56 isolates were resistant to at least eight drugs, and resistance to an increasing number of drugs was associated with the Beijing genotype (p=0·01). After 24 months of follow-up, 17 patients (16%) had a favourable outcome (ie, treatment cure or completion), 49 (46%) had died, seven (7%) had defaulted (interruption of treatment for at least 2 consecutive months), and 25 (23%) had failed treatment. At 60 months, 12 patients (11%) had a favourable outcome, 78 (73%) had died, four (4%) had defaulted, and 11 (10%) had failed treatment. 45 patients were discharged from hospital, of whom 26 (58%) had achieved sputum culture conversion and 19 (42%) had failed treatment. Median survival of patients who had failed treatment from time of discharge was 19·84 months (IQR 4·16-26·04). Clustering of cases and transmission within families containing a patient who had failed treatment and been discharged were shown with genotypic methods. Net sputum culture conversion occurred in 22 patients (21%) and median time to net culture conversion was 8·7 months (IQR 5·6-26·4). Independent predictors of probability of net culture conversion were no history of multidrug-resistant tuberculosis (p=0·0007) and use of clofazamine (p=0·0069). Independent overall predictors of survival were net culture conversion (p<0·0001) and treatment with clofazamine (p=0·021). Antiretroviral therapy was also a predictor of survival in patients with HIV (p=0·003). INTERPRETATION: In South Africa, long-term outcomes in patients with XDR tuberculosis are poor, irrespective of HIV status. Because appropriate long-stay or palliative care facilities are scarce, substantial numbers of patients with XDR tuberculosis who have failed treatment and have positive sputum cultures are being discharged from hospital and are likely to transmit disease into the wider community. Testing of new combined regimens is needed urgently and policy makers should implement interventions to minimise disease spread by patients who fail treatment. FUNDING: European and Developing Countries Clinical Trials Partnership, South African National Research Foundation (SARChI), and the South African Medical Research Council.
BACKGROUND: Long-term treatment-related outcomes in patients with extensively drug-resistant (XDR) tuberculosis are unknown. We followed up a cohort of patients to address knowledge gaps. METHODS: Between March, 2008, and August, 2012, we prospectively followed up a cohort of 107 patients from three provinces in South Africa, who had been diagnosed with XDR tuberculosis between August 2002, and February, 2008. Available isolates from 56 patients were genotyped to establish strain type and used for extended susceptibility testing. FINDINGS: All patients were treated empirically as inpatients with a median of eight drugs (IQR six to ten). 44 patients (41%) had HIV. 36 (64%) of 56 isolates were resistant to at least eight drugs, and resistance to an increasing number of drugs was associated with the Beijing genotype (p=0·01). After 24 months of follow-up, 17 patients (16%) had a favourable outcome (ie, treatment cure or completion), 49 (46%) had died, seven (7%) had defaulted (interruption of treatment for at least 2 consecutive months), and 25 (23%) had failed treatment. At 60 months, 12 patients (11%) had a favourable outcome, 78 (73%) had died, four (4%) had defaulted, and 11 (10%) had failed treatment. 45 patients were discharged from hospital, of whom 26 (58%) had achieved sputum culture conversion and 19 (42%) had failed treatment. Median survival of patients who had failed treatment from time of discharge was 19·84 months (IQR 4·16-26·04). Clustering of cases and transmission within families containing a patient who had failed treatment and been discharged were shown with genotypic methods. Net sputum culture conversion occurred in 22 patients (21%) and median time to net culture conversion was 8·7 months (IQR 5·6-26·4). Independent predictors of probability of net culture conversion were no history of multidrug-resistant tuberculosis (p=0·0007) and use of clofazamine (p=0·0069). Independent overall predictors of survival were net culture conversion (p<0·0001) and treatment with clofazamine (p=0·021). Antiretroviral therapy was also a predictor of survival in patients with HIV (p=0·003). INTERPRETATION: In South Africa, long-term outcomes in patients with XDR tuberculosis are poor, irrespective of HIV status. Because appropriate long-stay or palliative care facilities are scarce, substantial numbers of patients with XDR tuberculosis who have failed treatment and have positive sputum cultures are being discharged from hospital and are likely to transmit disease into the wider community. Testing of new combined regimens is needed urgently and policy makers should implement interventions to minimise disease spread by patients who fail treatment. FUNDING: European and Developing Countries Clinical Trials Partnership, South African National Research Foundation (SARChI), and the South African Medical Research Council.
Authors: E M Streicher; S L Sampson; K Dheda; T Dolby; J A Simpson; T C Victor; N C Gey van Pittius; P D van Helden; R M Warren Journal: J Clin Microbiol Date: 2015-09-02 Impact factor: 5.948
Authors: Thulasi Warrier; Kanishk Kapilashrami; Argyrides Argyrou; Thomas R Ioerger; David Little; Kenan C Murphy; Madhumitha Nandakumar; Suna Park; Ben Gold; Jianjie Mi; Tuo Zhang; Eugenia Meiler; Mike Rees; Selin Somersan-Karakaya; Esther Porras-De Francisco; Maria Martinez-Hoyos; Kristin Burns-Huang; Julia Roberts; Yan Ling; Kyu Y Rhee; Alfonso Mendoza-Losana; Minkui Luo; Carl F Nathan Journal: Proc Natl Acad Sci U S A Date: 2016-07-18 Impact factor: 11.205
Authors: Grant Theron; Jason Limberis; Rouxjeane Venter; Liezel Smith; Elize Pietersen; Aliasgar Esmail; Greg Calligaro; Julian Te Riele; Marianna de Kock; Paul van Helden; Tawanda Gumbo; Taane G Clark; Kevin Fennelly; Robin Warren; Keertan Dheda Journal: Nat Med Date: 2020-06-29 Impact factor: 53.440
Authors: Kathrin Zürcher; Marie Ballif; Lukas Fenner; Sonia Borrell; Peter M Keller; Joachim Gnokoro; Olivier Marcy; Marcel Yotebieng; Lameck Diero; E Jane Carter; Neesha Rockwood; Robert J Wilkinson; Helen Cox; Nicholas Ezati; Alash'le G Abimiku; Jimena Collantes; Anchalee Avihingsanon; Kamon Kawkitinarong; Miriam Reinhard; Rico Hömke; Robin Huebner; Sebastien Gagneux; Erik C Böttger; Matthias Egger Journal: Lancet Infect Dis Date: 2019-02-08 Impact factor: 25.071
Authors: N Padayatchi; M Gopal; R Naidoo; L Werner; K Naidoo; I Master; M R O'Donnell Journal: J Antimicrob Chemother Date: 2014-06-30 Impact factor: 5.790
Authors: John Z Metcalfe; Elizabeth Streicher; Grant Theron; Rebecca E Colman; Christopher Allender; Darrin Lemmer; Rob Warren; David M Engelthaler Journal: Am J Respir Crit Care Med Date: 2017-11-01 Impact factor: 21.405
Authors: Kristin N Nelson; N Sarita Shah; Barun Mathema; Nazir Ismail; James C M Brust; Tyler S Brown; Sara C Auld; Shaheed Vally Omar; Natashia Morris; Angie Campbell; Salim Allana; Pravi Moodley; Koleka Mlisana; Neel R Gandhi Journal: J Infect Dis Date: 2018-11-05 Impact factor: 5.226
Authors: A Carmona-Bayonas; P Jimenez-Fonseca; A Fernández-Somoano; F Álvarez-Manceñido; E Castañón; A Custodio; F A de la Peña; R M Payo; L P Valiente Journal: Clin Transl Oncol Date: 2017-12-07 Impact factor: 3.405